Attorney Docket No. Le A 33 820

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Haynes, et al.

Serial No.: 09/743,827

Group Art Unit: 1626

Filed: 07/31/01

Examiner: S.N. Wright

For: Antiparasitic Artemisinin Derivatives (endoperoxides)

CENTRAL FAX CENTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

JAN 1 9 2005

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below. with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313-1450.

Date: NOV- 10, 2004

Masselles Chandeles sel

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Sir:

The owner, BAYER AG, of 100% interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6.649.647. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that said prior patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal discialmer.

The Commissioner is hereby authorized to charge the Terminal disclaimer fee under 37 CFR 1.20(d) to Deposit Account 13-3372. A duplicate of this sheet is attached.

Respectfully submitted.

02/10/2005 VB/Rein

01 FC:1314

Telephones (203) 812-2786

Facsimile (203) 812-6459

Barbara A. Shimei Attorney of Record

Registration No.: 29, 862

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175

PAGE 4/14 * RCVD AT 1/19/2005 11:30:05 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/24 * DHIS:2738300 * CSID:203 812 5492 * DURATION (mm-ss):04-54